BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

New Brunswick Scientific (NBSC) Completes Merger Transaction with Eppendorf AG


9/25/2007 9:20:38 AM

EDISON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. ("NBS") , and Eppendorf Group ("Eppendorf") announced today the completion of the previously announced merger transaction in which Eppendorf acquired NBS for approximately $110 million in an all-cash transaction. As a result of the merger, which was approved by NBS' shareholders at a special meeting on September 20, 2007, NBS' shareholders are entitled to receive $11.50 per share in cash.

NBS has notified the NASDAQ Global Market of the closing of the transaction and expects that no further trading in NBS stock will occur after today and that its shares will no longer be listed. Eppendorf has appointed American Stock Transfer & Trust Company as paying agent, and, will promptly mail a letter of transmittal and instructions to all NBS shareholders of record. The letter of transmittal and instructions will contain information on how to surrender stock certificates representing shares of NBS common stock in exchange for $11.50 per share, without interest. NBS' shareholders of record should wait until they receive the letter of transmittal before surrendering their stock certificates. Shareholders who hold shares through a bank or broker will not have to take any action to have their shares exchanged for the merger consideration as such exchanges will be handled by the bank or broker.

About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global innovator providing a comprehensive line of equipment and instrumentation for the life science industry. NBS's products are used in the creation, maintenance and control of physical and biochemical environments required for the growth, detection and storage of microorganisms for medical, biological and chemical applications, environmental research and commercial products. Established in 1946, NBS is headquartered in Edison, New Jersey, with sales and distribution facilities located in the United States, Europe and Asia.

News releases and other information on NBS are available on the Internet at: http://www.nbsc.com.

About Eppendorf

Eppendorf is a global leader in laboratory equipment and associated consumables. Eppendorf products include liquid handling and centrifugation equipment products including related consumables as well as instruments and systems for PCR, cell technology and micro arrays that are used by researchers in life science, drug discovery, clinical, environmental and industrial laboratories. Founded in 1945, Eppendorf, a privately-held company headquartered in Hamburg, Germany, has revenues of more than $400 million, and employs approximately 2,000 people in over 20 countries.

News releases and other information on Eppendorf are available on the Internet at: http://www.eppendorf.com.

New Brunswick Scientific Co., Inc.

CONTACT: Investors, Thomas Bocchino, Vice President, Finance andTreasurer, of New Brunswick Scientific Co., Inc., +1-732-650-2500,tbocchino@nbsc.com; or Matthew J. Dennis, CFA, NBS Investor Relations, ofClear Perspective Group, LLC, +1-732-226-3030, mdennis@cpg-llc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->